Editorial: Myeloid-derived suppressor cells in inflammation and its complications and cancers.

Xing Li,Dinesh Kumar Ahirwar,Xiang-Yuan Wu

DOI: https://doi.org/10.3389/fimmu.2023.1240415

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 18 July 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1240415

What problem does this paper attempt to address?

Expansion of Myeloid Immune Suppressor Cells in Tumor-bearing Host Directly Promotes Tumor Angiogenesis, Tumor Growth, and Metastasis

Ping‐Chang Lin,Laura M. DeBusk,Jianhua Huang,Lynn M. Matrisian,Hal Moses,David P. Carbone,Li Yang

IF: 13.801

2007-01-01

Clinical Cancer Research

Abstract:PL02-02 Myeloid immune suppressor cells (MISCs), of myeloid macrophage/dendritic cell lineage, are significantly over-produced in the bone marrow and spleens of tumor-bearing mice as well as in peripheral blood of cancer patients. Interestingly, VEGF, the potent angiogenic factor and produced in most solid tumors, induces MISC production in vivo. In mice they express CD11b, a marker for myeloid cells of the macrophage lineage, and a marker for granulocytes, Gr-1. MISCs have been demonstrated to be immune suppressive since the 1980s. In this report, we demonstrate a novel tumor-promoting role of myeloid immune suppressor cells. These cells constitute 5% of total cells in solid tumors. Tumor cells coinjected with MISCs exhibited increased vascularization and decreased necrosis, as well as enhanced tumor growth. These immune cells produce high levels of MMP9. Deletion of MMP9 in these cells completely abolishes their tumor-promoting ability. MISCs were also found to directly incorporate into tumor endothelium. Consistent with this observation, MISCs acquire endothelial cell properties in tumor microenvironment and proangiogenic culture conditions. Furthermore, MISCs promote tumor metastasis through enhanced invasion. MISCs infiltrate into the invasive front with enhanced production and function of MMPs. Mice with 4T1 tumors co-injected with MISCs had significantly higher recurrent tumors at the injection site following surgical removal. 4T1 cells co-cultured with MISCs showed significantly increased invasion in vitro. Treatment with an MMP inhibitor significantly attenuated this process, suggesting a strong role of MISCs in tumor cell invasion through MMPs. In summary, MISCs are over-produced in tumor-bearing hosts, they can be re-programmed in multiple ways to promote tumor progression including angiogenesis, tumor growth and metastasis. Cellular and molecular targeting of MISC production should not only improve host immunosurveillance but also inhibit tumor metastasis, having the effect of “killing two birds with one stone.”
Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

SONG Yin-jing,WANG Qing-qing

DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2011.05.011

2011-01-01

International Journal of Immunology

Abstract:It has been established that cancer can be promoted by inflammation. Indeed, chronic inflammation orchestrates a tumor-supporting microenvironment that is an indispensable participant in the tumorigenesis and play critical roles at the different stages of tumor development. Myeloid-derived suppressor cells (MDSC)accumulate in response to pro-inflammatory mediators and they use a variety of mechanisms to block both innate and adaptive anti-tumor immunity. Because of their critical role in obstructing immune responses,MDSCs are a strategic obstacle to immunothe rapies that require activation of the host' s cell-mediated and innate immune responeses.
Editorial: Decoding Immunologic Complex Systems in Cancer: the Cutting-Edge Technologies Revolutionizing Cancer Immunology and Immunotherapy

Hu Li,Jin Zhang,Yuin Han Loh,Daniel D. Billadeau

DOI: https://doi.org/10.3389/fimmu.2023.1208589

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 04 May 2023Sec. Systems Immunology Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1208589
Editorial: The mechanism of immune cells in the development of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC).

Edda Russo,Kai Yin,Xiumei Sheng,Fei Mao,Amedeo Amedei

DOI: https://doi.org/10.3389/fimmu.2023.1218958

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 19 May 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1218958
Editorial: The cross-talk between cancer cells and immune cells in the tumor microenvironment

Tao Li,Bo Li,Qianqian Song,Wenjie Zheng

DOI: https://doi.org/10.3389/fmed.2023.1328045

IF: 3.9

2023-01-01

Frontiers in Medicine

Abstract:EDITORIAL article Front. Med., 16 November 2023Sec. Pathology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1328045
Myeloid-derived Suppressor Cells in Hematological Malignancies: Friends or Foes

Meng Lv,Ke Wang,Xiao‐Jun Huang

DOI: https://doi.org/10.1186/s13045-019-0797-3

IF: 28.5

2019-01-01

Journal of Hematology & Oncology

Abstract:Myeloid-derived suppressor cells (MDSCs) are newly identified immature myeloid cells that are characterized by the ability to suppress immune responses and expand during cancer, infection, and inflammatory diseases. Although MDSCs have attracted a lot of attention in the field of tumor immunology in recent years, little is known about their multiple roles in hematological malignancies as opposed to their roles in solid tumors. This review will help researchers better understand the various characteristics and functions of MDSCs, as well as the potential therapeutic applications of MDSCs in hematological malignancies, including lymphoma, multiple myeloma, leukemia, and hematopoietic stem cell transplantation.
Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity

Jun Dai,Mohamed El Gazzar,Guang Y. Li,Jonathan P. Moorman,Zhi Q. Yao

DOI: https://doi.org/10.1159/000368233

2014-01-01

Journal of Innate Immunity

Abstract:Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature suppressor cells that are generated due to aberrant myelopoiesis under pathological conditions. Although MDSCs have been recognized for more than 20 years under the guise of different monikers, these particular populations of myeloid cells gained more attention recently due to their immunosuppressive properties, which halt host immune responses to growing cancers or overwhelming infections. While MDSCs may contribute to immune homeostasis after infection or tissue injury by limiting excessive inflammatory processes, their expansion may be at the expense of pathogen elimination and thus may lead to disease persistence. Therefore, MDSCs may be either damaging or obliging to the host by attenuating, for example, antitumor or anti-infectious immune responses. In this review, we recapitulate the biological and immunological aspects of MDSCs, including their generation, distribution, trafficking and the factors involved in their activation, expansion, suppressive functions, and interplay between MDSCs and regulatory T cells, with a focus on the perspectives of infection and inflammation.
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Kyohei Nakamura,Mark J. Smyth

DOI: https://doi.org/10.1038/s41423-019-0306-1

2019-10-14

Cellular and Molecular Immunology

Abstract:Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of cancer. While innate immune cells, such as neutrophils, monocytes, and macrophages, are critical mediators for sterile and nonsterile inflammation, persistent inflammation, such as that which occurs in cancer, is known to disturb normal myelopoiesis. This disturbance leads to the generation of immunosuppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Due to their potent suppressive activities against effector lymphocytes and their abundance in the tumor microenvironment, immunosuppressive myeloid cells act as a major barrier to cancer immunotherapy. Indeed, various therapeutic approaches directed toward immunosuppressive myeloid cells are actively being tested in preclinical and clinical studies. These include anti-inflammatory agents, therapeutic blockade of the mobilization and survival of myeloid cells, and immunostimulatory adjuvants. More recently, immune checkpoint molecules expressed on tumor-infiltrating myeloid cells have emerged as potential therapeutic targets to redirect these cells to eliminate tumor cells. In this review, we discuss the complex crosstalk between cancer-related inflammation and immunosuppressive myeloid cells and possible therapeutic strategies to harness antitumor immune responses.

immunology
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation

Yuhui Yang,Chunyan Li,Tao Liu,Xiaofang Dai,Alexandr V. Bazhin

DOI: https://doi.org/10.3389/fimmu.2020.01371

IF: 7.3

2020-07-22

Frontiers in Immunology

Abstract:Among the various immunological and non-immunological tumor-promoting activities of myeloid-derived suppressor cells (MDSCs), their immunosuppressive capacity remains a key hallmark. Effort in the past decade has provided us with a clearer view of the suppressive nature of MDSCs. More suppressive pathways have been identified, and their recognized targets have been expanded from T cells and natural killer (NK) cells to other immune cells. These novel mechanisms and targets afford MDSCs versatility in suppressing both innate and adaptive immunity. On the other hand, a better understanding of the regulation of their development and function has been unveiled. This intricate regulatory network, consisting of tumor cells, stromal cells, soluble mediators, and hostile physical conditions, reveals bi-directional crosstalk between MDSCs and the tumor microenvironment. In this article, we will review available information on how MDSCs exert their immunosuppressive function and how they are regulated in the tumor milieu. As MDSCs are a well-established obstacle to anti-tumor immunity, new insights in the potential synergistic combination of MDSC-targeted therapy and immunotherapy will be discussed.

immunology
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Mithunah Krishnamoorthy,Lara Gerhardt,Saman Maleki Vareki

DOI: https://doi.org/10.3390/cells10051170

IF: 6

2021-05-11

Cells

Abstract:The primary function of myeloid cells is to protect the host from infections. However, during cancer progression or states of chronic inflammation, these cells develop into myeloid-derived suppressor cells (MDSCs) that play a prominent role in suppressing anti-tumor immunity. Overcoming the suppressive effects of MDSCs is a major hurdle in cancer immunotherapy. Therefore, understanding the mechanisms by which MDSCs promote tumor growth is essential for improving current immunotherapies and developing new ones. This review explores mechanisms by which MDSCs suppress T-cell immunity and how this impacts the efficacy of commonly used immunotherapies.

cell biology
Editorial: Genetic and epigenetic regulation of stem cells by the immune system in homeostasis, regeneration, and oncogenesis.

John M Perry,Pengxu Qian

DOI: https://doi.org/10.3389/fgene.2023.1230881

IF: 3.7

2023-01-01

Frontiers in Genetics

Abstract:EDITORIAL article Front. Genet., 14 June 2023Sec. Stem Cell Research Volume 14 - 2023 | https://doi.org/10.3389/fgene.2023.1230881
Myeloid-derived Suppressor Cells in Immunity and Autoimmunity

Hui Yang,Yujing Bi,Fei Han,Yun Lu,Jian Wang,Zhengguo Zhang,Guangwei Liu

DOI: https://doi.org/10.1586/1744666x.2015.1052794

2015-01-01

Expert Review of Clinical Immunology

Abstract:Myeloid-derived suppressor cells (MDSCs) play a critical role in suppressing immune responses in patients with cancer or severe inflammation. Recent studies have focused on the strong relationship between MDSCs and autoimmune diseases, such as autoimmune hepatitis, inflammatory bowel disease and experimental autoimmune encephalomyelitis. Interestingly, MDSCs appear to serve multifaceted functions in autoimmunity, playing both protective and pathogenic roles. Therefore, although MDSCs may be a functional target for the therapy of autoimmune diseases, the disorders that accompany such treatments should be noted. In this manuscript, we summarize the functions and molecular regulation of MDSCs in immunity and autoimmune disease.
Myeloid-derived suppressor cells in cancer and cancer therapy

Samantha A. Lasser,Feyza G. Ozbay Kurt,Ihor Arkhypov,Jochen Utikal,Viktor Umansky

DOI: https://doi.org/10.1038/s41571-023-00846-y

IF: 78.8

2024-01-09

Nature Reviews Clinical Oncology

Abstract:Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the considerable promise of cancer treatments that modulate the immune system. However, the immune system is complex and dynamic, and can have both tumour-suppressive and tumour-promoting effects. Understanding the full range of immune modulation in cancer is crucial to identifying more effective treatment strategies. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that develop in association with chronic inflammation, which is a hallmark of cancer. Indeed, MDSCs accumulate in the tumour microenvironment, where they strongly inhibit anticancer functions of T cells and natural killer cells and exert a variety of other tumour-promoting effects. Emerging evidence indicates that MDSCs also contribute to resistance to cancer treatments, particularly immunotherapies. Conversely, treatment approaches designed to eliminate cancer cells can have important additional effects on MDSC function, which can be either positive or negative. In this Review, we discuss the interplay between MDSCs and various other cell types found in tumours as well as the mechanisms by which MDSCs promote tumour progression. We also discuss the relevance and implications of MDSCs for cancer therapy.

oncology
Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad

Yongtong Ge,Dalei Cheng,Qingzhi Jia,Huabao Xiong,Junfeng Zhang

DOI: https://doi.org/10.4110/in.2021.21.e21

2021-01-01

Immune Network

Abstract:Myeloid-derived suppressor cells (MDSCs) have strong immunosuppressive activity and are morphologically similar to conventional monocytes and granulocytes. The development and classification of these cells have, however, been controversial. The activation network of MDSCs is relatively complex, and their mechanism of action is poorly understood, creating an avenue for further research. In recent years, MDSCs have been found to play an important role in immune regulation and in effectively inhibiting the activity of effector lymphocytes. Under certain conditions, particularly in the case of tissue damage or inflammation, MDSCs play a leading role in the immune response of the central nervous system. In cancer, however, this can lead to tumor immune evasion and the development of related diseases. Under cancerous conditions, tumors often alter bone marrow formation, thus affecting progenitor cell differentiation, and ultimately, MDSC accumulation. MDSCs are important contributors to tumor progression and play a key role in promoting tumor growth and metastasis, and even reduce the efficacy of immunotherapy. Currently, a number of studies have demonstrated that MDSCs play a key regulatory role in many clinical diseases. In light of these studies, this review discusses the origin of MDSCs, the mechanisms underlying their activation, their role in a variety of clinical diseases, and their function in immune response regulation.

immunology
Editorial: Acute-on-chronic Liver Failure: Systemic Inflammation and Immunosuppression

Olaf Tyc,Yu Shi,Yu-Chen Fan,Jonel Trebicka,Xiaogang Xiang

DOI: https://doi.org/10.3389/fimmu.2023.1260749

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:EDITORIAL article Front. Immunol., 15 August 2023Sec. Inflammation Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1260749
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Kai Li,Houhui Shi,Benxia Zhang,Xuejin Ou,Qizhi Ma,Yue Chen,Pei Shu,Dan Li,Yongsheng Wang

DOI: https://doi.org/10.1038/s41392-021-00670-9

IF: 39.3

2021-10-07

Signal Transduction and Targeted Therapy

Abstract:Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological activities. Besides, this group of cells are proved to impair the efficiency of current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs are considered as potential therapeutic targets for cancer therapy. Treatment strategies targeting MDSCs have shown promising outcomes in both preclinical studies and clinical trials when administrated alone, or in combination with other anticancer therapies. In this review, we shed new light on recent advances in the biological characteristics and immunosuppressive functions of MDSCs. We also hope to propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.

biochemistry & molecular biology,cell biology
Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy

Suncica Kapor,Milica Radojković,Juan F Santibanez

DOI: https://doi.org/10.1016/j.acthis.2024.152183

Abstract:Myeloid malignancies stem from a modified hematopoietic stem cell and predominantly include acute myeloid leukemia, myelodysplastic neoplasms, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid-derived suppressor cells (MDSCs) exhibit immunoregulatory properties by governing the innate and adaptive immune systems, creating a permissive and supportive environment for neoplasm growth. This review examines the key characteristics of MDSCs in myeloid malignancies, highlighting that an increased MDSC count corresponds to heightened immunosuppressive capabilities, fostering an immune-tolerant neoplasm microenvironment. Also, this review analyzes and describes the potential of combined cancer therapies, focusing on targeting MDSC generation, expansion, and their inherent immunosuppressive activities to enhance the efficacy of current cancer immunotherapies. A comprehensive understanding of the implications of myeloid malignancies may enhance the exploration of immunotherapeutic strategies for their potential application.
Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients

Jingwei Jiang,Weijian Guo,Xiaohua Liang

DOI: https://doi.org/10.1016/j.humimm.2014.09.025

IF: 2.211

2014-11-01

Human Immunology

Abstract:Myeloid-derived suppressor cells (MDSCs) comprise a group of heterogeneous and immature myeloid-derived cells. MDSCs accumulate in the blood, lymphoid organs, spleens and tumor tissues under different pathogenic conditions such as infection, trauma, hematosepsis, and especially oncogenesis. MDSCs can suppress both adaptive and innate immunities through multiple mechanisms. However, most of our knowledge of MDSCs is based on pre-clinical studies. Clinical observations have shown that the number of MDSCs in the peripheral blood of patients is closely related to tumor stage, tumor burden, remote metastasis and prognosis, though inconsistencies in MDSC phenotypes among cancer patients mean that results have been inconclusive, and subsequent research progress has been slow. This review summarizes recent studies that have investigated MDSCs in cancer patients.

immunology
Research Progress on Myeloid-Derived Suppressor Cells in Infective Diseases

WU Dan-xiao,XIA Da-jing

DOI: https://doi.org/10.3760/cma.j.issn.1673-4149.2008.06.011

2008-01-01

Abstract:Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of myeloid cells composed of immature dendritic cells, macrophages, granulocytes and other myeloid cells at early stages of differentiation. Infection and other diseases can induce the MDSC's accumulation in lymphoid organs and pathological site and, eventually, their acti-vation. These cells which have suppressive function can negatively regulate the immune system through several ways. Recent findings on the M DSC's phenotype, properties, recruiting and activating factors, mechanisms of immunoregulation and relations to infection diseases are summarized in the review.
Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer

Lingfei Li,Mingyang Li,Qingge Jia

DOI: https://doi.org/10.1016/j.prp.2023.154711

2023-07-26

Abstract:Myeloid-derived suppressor cell (MDSC) mainly exists in tumor microenvironment (TME) and interferes with normal immune response of the body. These immature differentiated cells cooperate with tumor cells for immune escape and proliferation. The subtypes of MDSC are different in different organisms, and STAT become a high priority for the signaling pathway mediating the regulation of MDSC. The surface of MDSC cell population contains a variety of signal molecular receptors, and its differentiation degree is toilless to be chemotaxis by different factors. The role of MDSC in silencing T cells and promoting regulatory T cells (Treg) is particularly significant. This review mainly contains the origin of MDSC, the characteristics of subgroups, the focus of the study on MDSC heat molecules and signaling pathways, the relationship between MDSC and carcinoma, prognosis and hope to propose an overview of current MDSCs- targeting therapies so as to provide new ideas for cancer treatment.

pathology

Editorial: Myeloid-derived suppressor cells in inflammation and its complications and cancers.

Expansion of Myeloid Immune Suppressor Cells in Tumor-bearing Host Directly Promotes Tumor Angiogenesis, Tumor Growth, and Metastasis

Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

Editorial: Decoding Immunologic Complex Systems in Cancer: the Cutting-Edge Technologies Revolutionizing Cancer Immunology and Immunotherapy

Editorial: The mechanism of immune cells in the development of inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC).

Editorial: The cross-talk between cancer cells and immune cells in the tumor microenvironment

Myeloid-derived Suppressor Cells in Hematological Malignancies: Friends or Foes

Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Editorial: Genetic and epigenetic regulation of stem cells by the immune system in homeostasis, regeneration, and oncogenesis.

Myeloid-derived Suppressor Cells in Immunity and Autoimmunity

Myeloid-derived suppressor cells in cancer and cancer therapy

Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad

Editorial: Acute-on-chronic Liver Failure: Systemic Inflammation and Immunosuppression

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy

Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients

Research Progress on Myeloid-Derived Suppressor Cells in Infective Diseases

Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer